<!-- Counter 17 — Anabólico primeiro: quando e por quê -->
<section
  class="slide"
  data-slide=""
  data-title="Anabólico primeiro: quando e por quê"
  id="slide-anabolic-first"
  style="
    padding: 32px 44px 16px 44px;
    background: var(--bg);
    display: flex;
    flex-direction: column;
    height: 100%;
    box-sizing: border-box;
  "
>
  <!-- Eyebrow -->
  <p
    style="
      font-family: var(--font-sans);
      font-size: 0.72vw;
      font-weight: 700;
      text-transform: uppercase;
      letter-spacing: 0.06em;
      color: var(--muted);
      margin: 0 0 4px 0;
    "
  >
    Tratamento orientado ao risco
  </p>

  <!-- Title -->
  <h1
    style="
      font-family: var(--font-sans);
      font-size: 2.1vw;
      font-weight: 800;
      color: var(--navy);
      line-height: 1.1;
      margin: 0 0 0.5vw 0;
      letter-spacing: -0.01em;
    "
  >
    Anabólico primeiro: quando e por quê
  </h1>

  <!-- 2-column layout — flex:1 fills vertical space -->
  <div style="display: grid; grid-template-columns: 1.15fr 0.85fr; gap: 1.2vw; margin-bottom: 0.5vw; flex: 1">
    <!-- LEFT: When — criteria with Tier 1 data -->
    <div style="display: flex; flex-direction: column; gap: 0.4vw; justify-content: space-between">
      <p
        style="
          font-family: var(--font-sans);
          font-size: 0.62vw;
          font-weight: 800;
          text-transform: uppercase;
          letter-spacing: 0.05em;
          color: var(--muted);
          margin: 0 0 0.1vw 0;
        "
      >
        Quando
      </p>

      <!-- Criterion 1 -->
      <div
        style="
          padding: 0.45vw 0.7vw;
          background: rgba(var(--navy-rgb), 0.03);
          border-left: 0.18vw solid var(--navy);
          border-radius: 0.3vw;
        "
      >
        <div style="display: flex; align-items: center; gap: 0.45vw">
          <span
            style="
              font-family: var(--font-sans);
              font-size: 0.65vw;
              font-weight: 800;
              color: var(--navy);
              background: rgba(var(--navy-rgb), 0.07);
              padding: 0.1vw 0.35vw;
              border-radius: 0.15vw;
              flex-shrink: 0;
            "
          >
            1
          </span>
          <p
            style="
              font-family: var(--font-sans);
              font-size: 0.82vw;
              font-weight: 700;
              color: var(--navy);
              margin: 0;
              line-height: 1.3;
            "
          >
            Fratura recente (≤ 2a) — vertebral, quadril ou pelve
          </p>
        </div>
        <p
          style="
            font-family: var(--font-sans);
            font-size: 0.62vw;
            color: var(--muted);
            margin: 0.15vw 0 0 1.8vw;
            line-height: 1.3;
          "
        >
          Risco 2,7× no 1º ano (Johansson Osteoporos Int 2017)
        </p>
      </div>

      <!-- Criterion 2 -->
      <div
        style="
          padding: 0.45vw 0.7vw;
          background: rgba(var(--navy-rgb), 0.03);
          border-left: 0.18vw solid var(--gold-dark);
          border-radius: 0.3vw;
        "
      >
        <div style="display: flex; align-items: center; gap: 0.45vw">
          <span
            style="
              font-family: var(--font-sans);
              font-size: 0.65vw;
              font-weight: 800;
              color: var(--gold-dark);
              background: rgba(var(--gold-dark-rgb), 0.07);
              padding: 0.1vw 0.35vw;
              border-radius: 0.15vw;
              flex-shrink: 0;
            "
          >
            2
          </span>
          <p style="font-family: var(--font-sans); font-size: 0.82vw; font-weight: 700; color: var(--navy); margin: 0">
            ≥ 2 fraturas vertebrais
          </p>
        </div>
        <p
          style="
            font-family: var(--font-sans);
            font-size: 0.62vw;
            color: var(--muted);
            margin: 0.15vw 0 0 1.8vw;
            line-height: 1.3;
          "
        >
          19% nova vertebral em 1 a (Lindsay JAMA 2001; IC 95% 14–25%)
        </p>
      </div>

      <!-- Criterion 3 -->
      <div
        style="
          padding: 0.45vw 0.7vw;
          background: rgba(var(--navy-rgb), 0.03);
          border-left: 0.18vw solid var(--gold-dark);
          border-radius: 0.3vw;
        "
      >
        <div style="display: flex; align-items: center; gap: 0.45vw">
          <span
            style="
              font-family: var(--font-sans);
              font-size: 0.65vw;
              font-weight: 800;
              color: var(--gold-dark);
              background: rgba(var(--gold-dark-rgb), 0.07);
              padding: 0.1vw 0.35vw;
              border-radius: 0.15vw;
              flex-shrink: 0;
            "
          >
            3
          </span>
          <p style="font-family: var(--font-sans); font-size: 0.82vw; font-weight: 700; color: var(--navy); margin: 0">
            T-score ≤ −3,0 com fratura prévia
          </p>
        </div>
        <p
          style="
            font-family: var(--font-sans);
            font-size: 0.62vw;
            color: var(--muted);
            margin: 0.15vw 0 0 1.8vw;
            line-height: 1.3;
          "
        >
          RR 2,6 (IC 95% 1,9–3,6) por SD no T-score (Cummings Lancet 1993)
        </p>
      </div>

      <!-- Criterion 4 -->
      <div
        style="
          padding: 0.45vw 0.7vw;
          background: rgba(var(--teal-rgb), 0.03);
          border-left: 0.18vw solid var(--teal);
          border-radius: 0.3vw;
        "
      >
        <div style="display: flex; align-items: center; gap: 0.45vw">
          <span
            style="
              font-family: var(--font-sans);
              font-size: 0.65vw;
              font-weight: 800;
              color: var(--teal);
              background: rgba(var(--teal-rgb), 0.07);
              padding: 0.1vw 0.35vw;
              border-radius: 0.15vw;
              flex-shrink: 0;
            "
          >
            4
          </span>
          <p style="font-family: var(--font-sans); font-size: 0.82vw; font-weight: 700; color: var(--navy); margin: 0">
            GIOP "very high risk" (ACR 2022)
          </p>
        </div>
        <p
          style="
            font-family: var(--font-sans);
            font-size: 0.62vw;
            color: var(--muted);
            margin: 0.15vw 0 0 1.8vw;
            line-height: 1.3;
          "
        >
          Perda 6-12% DMO trabecular no 1º ano de GC (Van Staa Osteoporos Int 2002)
        </p>
      </div>

      <!-- Criterion 5 -->
      <div
        style="
          padding: 0.45vw 0.7vw;
          background: rgba(var(--teal-rgb), 0.03);
          border-left: 0.18vw solid var(--teal);
          border-radius: 0.3vw;
        "
      >
        <div style="display: flex; align-items: center; gap: 0.45vw">
          <span
            style="
              font-family: var(--font-sans);
              font-size: 0.65vw;
              font-weight: 800;
              color: var(--teal);
              background: rgba(var(--teal-rgb), 0.07);
              padding: 0.1vw 0.35vw;
              border-radius: 0.15vw;
              flex-shrink: 0;
            "
          >
            5
          </span>
          <p style="font-family: var(--font-sans); font-size: 0.82vw; font-weight: 700; color: var(--navy); margin: 0">
            Falha de AR com adesão adequada
          </p>
        </div>
        <p
          style="
            font-family: var(--font-sans);
            font-size: 0.62vw;
            color: var(--muted);
            margin: 0.15vw 0 0 1.8vw;
            line-height: 1.3;
          "
        >
          Nova fratura ou DMO reduz &gt;5% com adesão ≥ 80%
        </p>
      </div>
    </div>

    <!-- RIGHT: Why — evidence head-to-head + NNTs -->
    <div style="display: flex; flex-direction: column; gap: 0.4vw; justify-content: space-between">
      <p
        style="
          font-family: var(--font-sans);
          font-size: 0.62vw;
          font-weight: 800;
          text-transform: uppercase;
          letter-spacing: 0.05em;
          color: var(--muted);
          margin: 0 0 0.1vw 0;
        "
      >
        Evidência head-to-head
      </p>

      <!-- VERO -->
      <div
        style="background: var(--white); border: 1px solid var(--border); border-radius: 0.4vw; padding: 0.5vw 0.7vw"
      >
        <div style="display: flex; justify-content: space-between; align-items: baseline; margin-bottom: 0.12vw">
          <span style="font-family: var(--font-sans); font-size: 0.75vw; font-weight: 800; color: var(--navy)">
            VERO
          </span>
          <span style="font-family: var(--font-sans); font-size: 0.55vw; color: var(--muted)">
            Kendler · Lancet 2018
          </span>
        </div>
        <p style="font-family: var(--font-sans); font-size: 0.6vw; color: var(--muted); margin: 0 0 0.1vw 0">
          Teriparatida vs risedronato · n=1.360 · 24m
        </p>
        <p
          style="
            font-family: var(--font-sans);
            font-size: 0.78vw;
            font-weight: 700;
            color: var(--gold-dark);
            margin: 0 0 0.12vw 0;
          "
        >
          Vertebral:
          <strong>5,4% vs 12,0%</strong>
          (RR 0,44; IC 95% 0,29–0,68)
        </p>
        <p style="font-family: var(--font-sans); font-size: 0.6vw; color: var(--navy); margin: 0; line-height: 1.3">
          Basal 12,0% → 5,4% · ARR 6,6% ·
          <strong style="color: var(--gold-dark)">NNT 15 (IC 95% 12–26)</strong>
          em 24 m
        </p>
      </div>

      <!-- FRAME -->
      <div
        style="background: var(--white); border: 1px solid var(--border); border-radius: 0.4vw; padding: 0.5vw 0.7vw"
      >
        <div style="display: flex; justify-content: space-between; align-items: baseline; margin-bottom: 0.12vw">
          <span style="font-family: var(--font-sans); font-size: 0.75vw; font-weight: 800; color: var(--navy)">
            FRAME
          </span>
          <span style="font-family: var(--font-sans); font-size: 0.55vw; color: var(--muted)">Cosman · NEJM 2016</span>
        </div>
        <p style="font-family: var(--font-sans); font-size: 0.6vw; color: var(--muted); margin: 0 0 0.1vw 0">
          Romosozumabe vs placebo · n=7.180 · 12m
        </p>
        <p
          style="
            font-family: var(--font-sans);
            font-size: 0.78vw;
            font-weight: 700;
            color: var(--gold-dark);
            margin: 0 0 0.12vw 0;
          "
        >
          Vertebral:
          <strong>0,5% vs 1,8%</strong>
          (RR 0,27; IC 95% 0,16–0,47)
        </p>
        <p style="font-family: var(--font-sans); font-size: 0.6vw; color: var(--navy); margin: 0; line-height: 1.3">
          Basal 1,8% → 0,5% · ARR 1,3% ·
          <strong style="color: var(--gold-dark)">NNT 77 (IC 95% 66–105)</strong>
          em 12 m
        </p>
      </div>

      <!-- ARCH -->
      <div
        style="background: var(--white); border: 1px solid var(--border); border-radius: 0.4vw; padding: 0.5vw 0.7vw"
      >
        <div style="display: flex; justify-content: space-between; align-items: baseline; margin-bottom: 0.12vw">
          <span style="font-family: var(--font-sans); font-size: 0.75vw; font-weight: 800; color: var(--navy)">
            ARCH
          </span>
          <span style="font-family: var(--font-sans); font-size: 0.55vw; color: var(--muted)">Saag · NEJM 2017</span>
        </div>
        <p style="font-family: var(--font-sans); font-size: 0.6vw; color: var(--muted); margin: 0 0 0.1vw 0">
          Romo → alendronato vs alendronato · n=4.093 · 24m
        </p>
        <p
          style="
            font-family: var(--font-sans);
            font-size: 0.78vw;
            font-weight: 700;
            color: var(--gold-dark);
            margin: 0 0 0.12vw 0;
          "
        >
          Vertebral:
          <strong>6,2% vs 11,9%</strong>
          (RR 0,52; p &lt; 0,001)
        </p>
        <p style="font-family: var(--font-sans); font-size: 0.6vw; color: var(--navy); margin: 0; line-height: 1.3">
          Basal 11,9% → 6,2% · ARR 5,7% ·
          <strong style="color: var(--gold-dark)">NNT 18 (IC 95% 13–25)</strong>
          em 24 m
        </p>
      </div>

      <!-- Bridge to next slide -->
      <div
        style="
          background: rgba(var(--gold-rgb), 0.05);
          border-left: 0.2vw solid var(--gold-dark);
          border-radius: 0.3vw;
          padding: 0.45vw 0.7vw;
        "
      >
        <p
          style="
            font-family: var(--font-sans);
            font-size: 0.72vw;
            font-weight: 600;
            color: var(--navy);
            margin: 0;
            line-height: 1.3;
          "
        >
          <strong style="color: var(--gold-dark)">E se invertermos a ordem?</strong>
          AR prévio → quiescência osteoblástica → resposta atenuada (
          <em>blunting effect</em>
          →)
        </p>
      </div>
    </div>
  </div>

  <!-- Take-home -->
  <div
    style="
      background: var(--navy);
      border-radius: 0.45vw;
      padding: 0.6vw 1.1vw;
      display: flex;
      align-items: center;
      gap: 0.8vw;
      margin-bottom: 0.45vw;
    "
  >
    <span
      style="
        font-family: var(--font-sans);
        font-size: 0.6vw;
        font-weight: 700;
        color: var(--navy);
        background: var(--gold);
        padding: 0.18vw 0.45vw;
        border-radius: 0.22vw;
        text-transform: uppercase;
        letter-spacing: 0.04em;
        flex-shrink: 0;
      "
    >
      Takeaway
    </span>
    <p
      style="
        font-family: var(--font-sans);
        font-size: 0.78vw;
        font-weight: 500;
        color: var(--white);
        margin: 0;
        line-height: 1.3;
      "
    >
      Muito alto risco ou iminente:
      <strong style="color: var(--gold)">anabólico primeiro</strong>
      — redução precoce de fraturas e maior ganho de DMO.
    </p>
  </div>

  <!-- References -->
  <p style="font-family: var(--font-sans); font-size: 0.52vw; color: var(--muted); margin: 0; line-height: 1.4">
    Kendler DL et al. Lancet 2018;391:230-40 (VERO). Cosman F et al. NEJM 2016;375:1532-43 (FRAME). Saag KG et al. NEJM
    2017;377:1417-27 (ARCH). Cosman F et al. JBMR 2024;39(10):1393-1405.
  </p>
</section>
